Results 241 to 250 of about 104,823 (289)

From Leukemia to Solid Tumors, Successful Multidisciplinary Management of Three Distinct Primary Cancers in a Single Patient: A Case Report

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT A 41‐year‐old man developed three distinct primary malignancies—acute myeloid leukemia, male breast cancer, and metastatic colorectal cancer—within 7 years. This rare case highlights the evolving challenge of multiple primary cancers and demonstrates how coordinated multidisciplinary care can preserve curative intent despite successive life ...
Abolfazl Khalafi‐Nezhad, Nazanin Alemzadeh, Mohammad Hossein Anbardar, Zahra Ghanbarinasab   +3 more
wiley   +1 more source

Integrating antibody–drug conjugates into solid tumor oncology: Current standards and future directions

Cancer, Volume 132, Issue S1, 1 June 2026.
Abstract Antibody–drug conjugates (ADCs) represent a major advance in precision oncology, combining the selectivity of monoclonal antibodies with the cytotoxic potency of chemotherapy. By enabling targeted intracellular delivery of highly potent payloads, ADCs aim to maximize antitumor activity while minimizing systemic toxicity. This review summarizes
André Mansinho, Joana Albuquerque, Andreia Lopes, Emiliano Calvo   +3 more
wiley   +1 more source

First‐line envafolimab plus recombinant human‐endostatin in advanced non–small cell lung cancer with PD‐L1 tumor proportion score ≥1% (Endouble): A multicenter, prospective, single‐arm, phase 2 trial

Cancer, Volume 132, Issue 11, 1 June 2026.
Envafolimab combined with recombinant human endostatin demonstrates favorable efficacy and tolerable toxicity in non–small cell lung cancer patients. MMP1 and TNFRSF6B may be predictive biomarkers for treatment response. Abstract Background This trial evaluates the efficacy and safety of combining envafolimab and recombinant human endostatin (Rh ...
Changhong Dong, Liang Liu, Yun Qiao, Mei Wang, Daan Song, Lihua Zhou, Yajun Ji, Yan Li, Fendou Ding, Hao Wang, Min Zhuang, Lei Wang, Zhenghong Liu, Haitao Fei, Xiangjun Guo, Baoxiang Bian, Chunluan Yuan, Guanghui Xu, Lijian Fang, Yan Li, Ziyan Song, Kaiyuan Hui, Xiaodong Jiang   +22 more
wiley   +1 more source

Methyltransferase‐Like 14 Promotes the Angiogenesis of Hepatocellular Carcinoma via Targeting Vascular Endothelial Growth Factor A

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background N6‐methyladenosine (m6A) modification is a pivotal epitranscriptomic regulator implicated in tumor progression. As a core component of the m6A methyltransferase complex, METTL14 is known to suppress tumorigenesis; however, its specific role in tumor angiogenesis remains elusive. Given that Vascular Endothelial Growth Factor A (VEGFA)
Xinmiao Xiong, Chuanfang Shu, Ziqun Qu, Jiayan Li, Wei Ye, Lili Wang   +5 more
wiley   +1 more source

Systemic Treatment of Advanced Chordoma With Molecular Targeted Therapies: A Large Multicentre European Retrospective Case Series

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background This retrospective series reports outcomes and prognostic factors for advanced chordoma (AC) treatment with molecular targeted therapies (MTTs) in different treatment lines. Methods This is a retrospective series of 57 patients with AC treated between 2004 and 2023 at one of seven participating sarcoma centres.
Astrid Lipplaa, Nadia Hindi, Pawel Teterycz, Robin J. Young, Ioannis Boukonavis, Josefina Cruz, Javier Martinez‐Trufero, Frank Speetjens, Wilco Peul, Robert J. P. van der Wal, Hans Gelderblom   +10 more
wiley   +1 more source

Extracellular Vesicles as Drivers of Lung Endothelial Dysfunction in ARDS: Mechanisms and Therapeutic Opportunities

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
This review summarizes how extracellular vesicles from diverse pulmonary and extrapulmonary sources contribute to endothelial dysfunction in ARDS and evaluates emerging endothelial‐targeted therapies for their potential to mitigate EV‐mediated pathogenic mechanisms.
Mohammed Yaman Al Matni, Patrick Belvitch, Steven M. Dudek, Eleftheria Letsiou   +3 more
wiley   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1476-1484, June 2026.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma. [PDF]

PLoS One
Xu X, Tang L, Piao X, Zhan S, Chen Y, Feng P.   +5 more
europepmc   +1 more source

Efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents in advanced cervical cancer: a systematic review and meta-analysis. [PDF]

Front Immunol
Zhang D, Meng Y, Dong X, Huang C, Ding X, Wu M, Gao K, Chang X, Ou Y, Dong M.   +9 more
europepmc   +1 more source